Suggested remit: To appraise the clinical and cost effectiveness of avacopan within its marketing authorisation for treating anti-neutrophil cytoplasmic antibody-associated vasculitis.
Status Proposed
Process STA
ID number 1178

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
17 August 2017 The consultation on the draft scope closed on Tuesday 15 August 2017. The company that markets the technology has advised that the regulatory filing strategy for this product is delayed and still under consideration. NICE has agreed that a scoping workshop would not be appropriate at this time. As a consequence of this the scoping workshop arranged for 15 September 2017 has been cancelled. We apologise for any inconvenience this may cause.
18 July 2017 - 15 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance